Chronic Kidney Disease trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Chronic Kidney Disease. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisNCT06901505Change in hemoglobin (Hb) | Phase 3 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-02-23 |
September 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNCT06717698Change in urinary albumin-to-creatinine ratio (UACR) at week 12 | Phase 2 | Recruiting | 2026-09-01 | in 12 d | 2026-03-11 |
| LLY | Eli Lilly and Company | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804Percent Change from Baseline in Renal Sinus Fat Content (MRI) | Phase 2 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-05-08 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional CohortNCT07024823Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | 2026-12-25 | in 127 d | 2026-08-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Chronic Kidney Disease
most recently updated first232 studies match. Showing the first 100 of 232 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HUMA | Humacyte, Inc. | $162M | Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisNCT02644941results2025-03-30Number of Participants With Loss of Secondary Patency | Phase 3 | Completed | Biological: Human Acellular Vessel (HAV) · Device: ePTFE graft | Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access | 355 | 2016-05-24 | May 2019actual | — | 2026-08-19 |
| AZN | AstraZeneca | — | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)NCT06087835Change in eGFR from baseline | Phase 3 | Active, not recruiting | Drug: Zibotentan/Dapagliflozin, Dapagliflozin | Chronic Kidney Disease With High Proteinuria | 1,835 | 2023-11-07 | 2027-02-18 | in 182 d | 2026-08-19 |
| AZN | AstraZeneca | — | Chronic Kidney Disease Registry Platform StudyNCT06117852observationalDisease Progression in CKD Patients | — | Active, not recruiting | — | Chronic Kidney Diseases | 5,000 | 2023-11-28 | 2028-11-30 | in 833 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Prospecitve Multicenter, Observational Registry StudyNCT07481526observationalProportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively | — | Recruiting | — | Chronic Kidney Disease | 3,000 | 2026-02-27 | 2028-12-30 | in 863 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional CohortNCT07024823Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: AZD4248, Placebo, AZD4248, Placebo | Chronic Kidney Disease | 124 | 2025-06-09 | 2026-12-25 | in 127 d | 2026-08-12 |
| PROK | Prokidney | $85M | Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseNCT05099770Surrogate / Intermediate Efficacy Endpoint -eGFR Slope | Phase 3 | Active, not recruiting | Biological: Renal Autologous Cell Therapy (REACT/ rilparencel) · Procedure: Sham Comparator | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 685 | 2022-01-05 | Dec 2029 | ≤ 1,229 d | 2026-08-11 |
| AZN | AstraZeneca | — | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.NCT07753993To evaluate the effect of elecoglipron compared with placebo in reducing the risk of the composite of ≥ 50% sustained decline in eGFR, ESKD, or all-cause mortality | Phase 3 | Not yet recruiting | Drug: Elecoglipron, Placebo | Chronic Kidney Disease | 7,000 | 2026-08-28 | 2030-10-04 | in 1,506 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events | Phase 3 | Recruiting | Drug: Orforglipron, Placebo | Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease | 7,140 | 2025-12-01 | Aug 2031 | ≤ 1,837 d | 2026-08-06 |
| NVO | Novo Nordisk A/S | — | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationNCT05021835Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal stroke | Phase 3 | Completed | Drug: Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C) | Cardiovascular Risk, Chronic Kidney Disease, Inflammation | 6,385 | 2021-08-30 | 2026-06-09actual | — | 2026-07-28 |
| AZN | AstraZeneca | — | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death. | Phase 3 | Recruiting | Drug: Baxdrostat/dapagliflozin, Placebo/dapagliflozin | Chronic Kidney Disease and Hypertension | 5,000 | 2025-03-03 | 2029-12-18 | in 1,216 d | 2026-07-28 |
| AZN | AstraZeneca | — | iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754observational1. Age of particpants | — | Recruiting | — | Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure | 35,000 | 2018-02-17 | 2030-12-31 | in 1,594 d | 2026-07-22 |
| REGN | Regeneron Pharmaceuticals | $76.1B | An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney TransplantNCT05106387observationalIncidence of Adverse Events | — | Recruiting | Drug: Noninterventional | Chronic Kidney Disease (CKD) | 20 | 2023-10-19 | 2027-06-14 | in 298 d | 2026-07-20 |
| LLY | Eli Lilly and Company | $1.15T | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390Time to First Occurrence of Composite Endpoints | Phase 3 | Active, not recruiting | Drug: Retatrutide, Placebo | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 10,000 | 2024-04-30 | Feb 2029 | ≤ 923 d | 2026-07-20 |
| NVO | Novo Nordisk A/S | — | Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based StudyNCT07673822observationalProportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2)) | — | Enrolling by invitation | Other: No treatment given | Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk | 800,000 | 2026-06-08 | 2026-08-03 | — | 2026-06-29 |
| HUMA | Humacyte, Inc. | $162M | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084The number of catheter-free days since randomization to Month 12. | Phase 3 | Active, not recruiting | Biological: Acellular Tissue Engineered Vessel (ATEV) · Other: AVF | End Stage Renal Disease (ESRD) | 121 | 2023-09-07 | Jun 2027 | ≤ 314 d | 2026-06-26 |
| AZN | AstraZeneca | — | A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.NCT06268873To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR over time. | Phase 3 | Active, not recruiting | Drug: Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo | Chronic Kidney Disease and Hypertension | 2,554 | 2024-03-29 | 2028-02-24 | in 553 d | 2026-06-26 |
| AZN | AstraZeneca | — | Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney DiseaseNCT06350123results2026-06-26Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12 | Phase 2 | Completed | Drug: Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin | Chronic Kidney Disease | 324 | 2024-05-01 | 2025-05-09actual | — | 2026-06-26 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)NCT04064827results2026-06-15Percentage of Participants Who Achieve Positive Response During Dosing Period 1 | Phase 3 | Terminatedsponsor's stated reason: Company Decision | Drug: Paricalcitol | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | 2 | 2020-09-16 | 2025-06-09actual | — | 2026-06-15 |
| MLYS | Mineralys Therapeutics Inc. | $2.3B | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaNCT06150924results2026-06-03Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 | Phase 2 | Completed | Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD | Chronic Kidney Disease | 60 | 2023-12-14 | 2025-02-27actual | — | 2026-06-03 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)NCT05092347Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period | Phase 1/2 | Active, not recruiting | Drug: Vonsetamig | Chronic Kidney Disease (CKD) | 43 | 2022-08-02 | 2027-11-22 | in 459 d | 2026-06-02 |
| MMSI | Merit Medical Systems, Inc. | $5.3B | PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on HemodialysisNCT06422871observationalComposite Endpoint | — | Recruiting | Device: HeRO® Graft System or Super HeRO® System | End Stage Renal Disease, Hemodialysis Access Failure | 100 | 2025-07-28 | 2027-06-28 | in 312 d | 2026-06-01 |
| UTHR | United Therapeutics | $22.2B | Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDNCT07224763Survival Rate of Patients with ESRD Receiving the GGTA1 KO Thymokidney at 24 Weeks Post Transplant | Phase 1/2 | Recruiting | Biological: GGTA1 KO Thymokidney | ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation | 50 | Jun 2026 | Mar 2029 | ≤ 954 d | 2026-05-27 |
| AZN | AstraZeneca | — | OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKDNCT07450820observationalBaseline demographics and clinical characteristics (comorbidities) of the study cohorts | — | Completed | — | Chronic Kidney Disease | 12,894 | 2026-02-18 | 2026-05-06actual | — | 2026-05-27 |
| AZN | AstraZeneca | — | A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.NCT07222917To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria. | Phase 2 | Recruiting | Drug: Baxdrostat/dapagliflozin, Baxdrostat/Placebo | Chronic Kidney Disease and Hypertension | 218 | 2025-12-05 | 2027-05-24 | in 277 d | 2026-05-18 |
| AZN | AstraZeneca | — | To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian PatientsNCT05866276observationalSensitivity and Specificity | — | Completed | — | Chronic Kidney Disease | 1,426 | 2023-06-22 | 2024-05-31actual | — | 2026-05-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804Percent Change from Baseline in Renal Sinus Fat Content (MRI) | Phase 2 | Active, not recruiting | Drug: Tirzepatide, Placebo | Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D | 140 | 2023-02-08 | Sep 2026 | ≤ 41 d | 2026-05-08 |
| NVO | Novo Nordisk A/S | — | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.NCT04626505results2026-05-06Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12) | Phase 2 | Completed | Drug: Ziltivekimab, Placebo (ziltivekimab) | Chronic Kidney Disease, Inflammation, Cardiovascular Risk | 36 | 2020-10-22 | 2021-08-03actual | — | 2026-05-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal ImpairmentNCT07165015Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537031 | Phase 1 | Completed | Drug: LY3537031 | Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD) | 31 | 2025-09-18 | 2026-04-16actual | — | 2026-04-24 |
| IRON | Disc Medicine, Inc | $3.1B | Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and AnemiaNCT05745883Incidence of treatment-emergent adverse events | Phase 1 | Completed | Drug: DISC-0974, Placebo | Chronic Kidney Diseases, Anemia of Chronic Kidney Disease | 55 | 2023-04-04 | 2025-10-09actual | — | 2026-04-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death] | Phase 3 | Completed | Drug: Orforglipron, Insulin Glargine | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 2,749 | 2023-04-03 | 2026-03-16actual | — | 2026-04-17 |
| AZN | AstraZeneca | — | A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaNCT06942910Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline | Phase 2 | Recruiting | Drug: Zibotentan/Dapagliflozin, Dapagliflozin | Chronic Kidney Disease With High Proteinuria | 224 | 2025-05-07 | 2026-07-31 | — | 2026-04-17 |
| OPK | OPKO Health, Inc. | $1.0B | Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDINCT03602261results2025-03-30Number of Participants With Response During Efficacy Assessment Period | Phase 2 | Terminatedsponsor's stated reason: Cohort 1 completed and cohort 2 terminated prior to initiation per company decision | Drug: Calcifediol Oral Capsule, Placebo oral capsule | Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease | 44 | 2018-07-09 | 2021-02-24actual | — | 2026-04-03 |
| NVO | Novo Nordisk A/S | — | A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372Change in urinary albumin-to-creatinine ratio (UACR) | Phase 2 | Completed | Drug: Cagrilintide, Semaglutide, Placebo | Chronic Kidney Disease, Type 2 Diabetes, Obesity | 626 | 2024-04-01 | 2025-09-24actual | — | 2026-04-01 |
| OPK | OPKO Health, Inc. | $1.0B | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsNCT07494045Apparent clearance (CL/F) | Phase 2 | Not yet recruiting | Drug: CTAP101 | CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI | 40 | Jun 2026 | Oct 2027 | ≤ 437 d | 2026-03-30 |
| UTHR | United Therapeutics | $22.2B | Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRDNCT06878560Survival Rate of Patients with ESRD Receiving the 10 GE Xenokidney at 24 Weeks Post Transplant | Phase 1/2 | Recruiting | Biological: 10 GE Xenokidney | ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation | 50 | 2025-10-29 | Oct 2028 | ≤ 803 d | 2026-03-27 |
| AMGN | Amgen | $229.9B | A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)NCT06468826results2026-03-25Maximum Observed Plasma Concentration (Cmax) of Avacopan | Phase 1 | Completed | Drug: Avacopan | End-Stage Renal Disease (ESRD) | 13 | 2024-06-18 | 2024-10-05actual | — | 2026-03-25 |
| PROK | Prokidney | $85M | Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)NCT05018416Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation | Phase 2 | Completed | Biological: Renal Autologous Cell Therapy (REACT) | Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 53 | 2021-07-27 | 2025-05-20actual | — | 2026-03-13 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNCT06717698Change in urinary albumin-to-creatinine ratio (UACR) at week 12 | Phase 2 | Recruiting | Drug: NNC0519-0130, Placebo, Semaglutide | Chronic Kidney Disease | 465 | 2024-12-02 | 2026-09-01 | in 12 d | 2026-03-11 |
| NVO | Novo Nordisk A/S | — | A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy PeopleNCT07029568PART A: Number of treatment emergent adverse events (TEAE) | Phase 1 | Completed | Drug: NNC0705-0001, Placebo | Healthy Volunteers, Chronic Kidney Disease | 116 | 2025-06-13 | 2025-11-04actual | — | 2026-03-11 |
| AMGN | Amgen | $229.9B | A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisNCT03633708Percentage of Participants Achieving a ≥ 30% Reduction from Baseline in Mean iPTH During the Efficacy Assessment Period (EAP) | Phase 3 | Recruiting | Drug: Etelcalcetide · Other: Standard of Care | Secondary Hyperparathyroidism, Chronic Kidney Disease | 56 | 2019-04-29 | 2029-01-31 | in 895 d | 2026-02-27 |
| AKBA | Akebia Therapeutics | $236M | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisNCT06901505Change in hemoglobin (Hb) | Phase 3 | Active, not recruiting | Drug: Erythropoiesis-Stimulating Agent (ESA), Vadadustat | Anemia of Chronic Kidney Disease | 353 | 2025-07-24 | Aug 2026 | ≤ 11 d | 2026-02-23 |
| NVO | Novo Nordisk A/S | — | Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure ManagementNCT07160829observationalPerceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease | 608 | 2025-09-18 | 2025-10-30actual | — | 2026-02-11 |
| NVO | Novo Nordisk A/S | — | A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)NCT04865770results2026-01-14Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*) | Phase 3 | Completed | Drug: Semaglutide, Placebo (Semaglutide) | Diabetes Mellitus, Type 2, Chronic Kidney Disease | 106 | 2021-04-28 | 2024-11-21actual | — | 2026-02-10 |
| AZN | AstraZeneca | — | A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney DiseaseNCT06610526Time to the first occurrence of any of the components of the composite: 50% sustained decline in eGFR or Reaching ESRD or CV Death or Renal Death. | Phase 4 | Active, not recruiting | Drug: Dapagliflozin | Chronic Kidney Disease | 731 | 2024-08-23 | 2027-05-31 | in 284 d | 2026-01-30 |
| NVO | Novo Nordisk A/S | — | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 InhibitionNCT03926117results2023-08-09Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels | Phase 2 | Completed | Biological: Ziltivekimab | Chronic Kidney Diseases, Inflammation | 264 | 2019-06-03 | 2020-06-26actual | — | 2025-12-31 |
| NVO | Novo Nordisk A/S | — | A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and NephrologistsNCT06589791observationalHealth care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 1,500 | 2024-09-09 | 2024-12-05actual | — | 2025-12-05 |
| AZN | AstraZeneca | — | Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge StudyNCT05347693results2025-11-28Occurrence (Yes/No) of NK (K+ Between 3.5 and 5.0 mmol/L, Inclusive) at 180 Days Post-discharge | Phase 4 | Completed | Drug: Sodium Zirconium Cyclosilicate (SZC), Local standard of care | Hyperkalaemia, Chronic Kidney Disease | 186 | 2022-03-24 | 2024-12-10actual | — | 2025-11-28 |
| AZN | AstraZeneca | — | A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.NCT06675175Number of participants with adverse events | Phase 1 | Completed | Drug: AZD4144 · Other: Placebo | Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease | 29 | 2024-12-09 | 2025-10-27actual | — | 2025-11-25 |
| HUMA | Humacyte, Inc. | $162M | Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisNCT03183245Proportion of subjects with functional patency at 6 months post study access (SA) creation | Phase 3 | Completed | Biological: Human Acellular Vessel (HAV) · Procedure: Arteriovenous fistula (AVF) · Other: Hemodialysis | Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access | 242 | 2017-09-29 | 2024-04-22actual | — | 2025-11-20 |
| REVB | Revelation Biosciences, Inc | $4M | Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.NCT06863467Effect of Gemini versus placebo on the incidence of treatment-emergent adverse events. | Phase 1/2 | Completed | Drug: Intravenous Gemini, Intravenous placebo | Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | 40 | 2025-01-20 | 2025-07-22actual | — | 2025-10-29 |
| AZN | AstraZeneca | — | Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease PatientsNCT06203704observationalDapagliflozin utilisation: to describe characteristics among patients who are treated with dapagliflozin. | — | Completed | — | Chronic Kidney Disease (CKD) | 1,086 | 2023-12-20 | 2025-09-30actual | — | 2025-10-28 |
| AZN | AstraZeneca | — | Forxiga CKD Japan Post-Marketing Surveillance (PMS)NCT05306210observationalIncidence of ADRs during use of Forxiga in the real world setting | — | Completed | — | Chronic Kidney Disease | 1,029 | 2022-04-12 | 2024-10-08actual | — | 2025-10-09 |
| LLY | Eli Lilly and Company | $1.15T | Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney DiseaseNCT06598631Percent Change from Baseline of Urine Albumin-Creatinine Ratio (UACR) | Phase 2 | Withdrawnsponsor's stated reason: Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group. | Drug: Volenrelaxin, Placebo | Chronic Kidney Disease | 0 | 2024-10-09 | 2024-12-30actual | — | 2025-10-02 |
| AKBA | Akebia Therapeutics | $236M | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseNCT05082571Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28) | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: vadadustat | Anemia of Chronic Kidney Disease | 0 | Jan 2025 | Jul 2026 | — | 2025-10-01 |
| AKBA | Akebia Therapeutics | $236M | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsNCT05082584Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28) | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: Vadadustat | Anemia of Chronic Kidney Disease | 0 | Jan 2025 | Jul 2026 | — | 2025-10-01 |
| HUMA | Humacyte, Inc. | $162M | Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis AccessNCT07141641expanded access | — | Temporarily not available | Biological: Acellular Tissue Engineered Vessel (ATEV) | Vascular Diseases, End Stage Renal Disease on Dialysis | — | — | — | — | 2025-09-15 |
| PROK | Prokidney | $85M | A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseNCT02836574Change in Renal Function | Phase 2 | Completed | Biological: Renal Autologous Cell Therapy (REACT) · Procedure: Renal Biopsy | Type 2 Diabetes Mellitus, Chronic Kidney Disease | 83 | Sep 2016 | Dec 2023actual | — | 2025-08-24 |
| OPK | OPKO Health, Inc. | $1.0B | Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismNCT05543928results2025-07-25Numbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline | Phase 3 | Terminatedsponsor's stated reason: FDA changed the post-marketing requirement necessitating a new study design and protocol. | Drug: CTAP101, Placebo | Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism | 2 | 2023-01-31 | 2024-06-19actual | — | 2025-07-25 |
| AZN | AstraZeneca | — | A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsNCT05294458Absolute bioavailability of the high and the low concentration cotadutide SC formulations | Phase 1 | Completed | Drug: cotadutide solution for injection | Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease | 10 | 2022-03-28 | 2022-09-12actual | — | 2025-07-20 |
| PAVM | PAVmed Inc. | $40M | PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion SystemNCT06037265Primary Performance | Not applicable | Completed | Device: PAVmed PortIO™ Intraosseous Infusion System | Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Poor Vascular Access | 15 | 2022-01-20 | 2024-07-29actual | — | 2025-06-27 |
| BIIB | Biogen | $31.4B | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)NCT03749447results2024-03-19Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 3 | Terminatedsponsor's stated reason: Discontinuation of all bardoxolone chronic kidney disease programs | Drug: Bardoxolone methyl | Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney | 270 | 2019-03-08 | 2023-08-23actual | — | 2025-06-03 |
| BIIB | Biogen | $31.4B | A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)NCT04702997results2022-12-01Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 | Phase 2 | Completed | Drug: Bardoxolone methyl oral capsule, Placebo oral capsule | Chronic Kidney Diseases | 81 | 2021-02-09 | 2021-10-20actual | — | 2025-06-03 |
| BIIB | Biogen | $31.4B | Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseNCT00811889To determine the change in eGFR from baseline in patients with type 2 diabetes and CKD (baseline eGFR = 20 - 45 mL/min/1.73m2) after receiving bardoxolone methyl for 6 months (24 weeks) following randomization | Phase 2 | Completed | Other: Placebo · Drug: Bardoxolone Methyl (RTA 402) | Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy | 227 | 2009-04-30 | 2010-05-31actual | — | 2025-05-29 |
| BIIB | Biogen | $31.4B | A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal DialysisNCT01576887Number of Adverse Events | Phase 2 | Withdrawnsponsor's stated reason: IDMC recommendation for safety concerns | Drug: Bardoxolone Methyl 20 mg, Placebo | End-Stage Renal Disease, Type 2 Diabetes Mellitus | 0 | 2012-07-31 | 2012-10-31actual | — | 2025-05-29 |
| PROK | Prokidney | $85M | A Long-Term Follow-Up Study of Participants Exposed to REACTNCT05918523observationalPrimary Endpoint: Long-term safety of REACT | — | Recruiting | Biological: Renal Autologous Cell Therapy (REACT) | Diabetic Kidney Disease, Chronic Kidney Diseases | 80 | 2023-12-11 | Jan 2028 | ≤ 529 d | 2025-05-28 |
| AZN | AstraZeneca | — | A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney DiseaseNCT05432167results2025-05-20Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo | Phase 2 | Completed | Drug: CIN-107, Placebo | Uncontrolled Hypertension, Chronic Kidney Diseases | 195 | 2022-04-29 | 2024-05-02actual | — | 2025-05-20 |
| NVO | Novo Nordisk A/S | — | Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)NCT06122961observationalHigh sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L (yes/ no) | — | Completed | Other: No treatment given | Cardiovascular Risk, Heart Failure, Chronic Kidney Disease | 18,198 | 2023-11-23 | 2025-04-30actual | — | 2025-05-09 |
| PROK | Prokidney | $85M | A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney DiseaseNCT03270956results2025-03-24Procedure and/or Product Related Adverse Events | Phase 2 | Completed | Biological: Renal Autologous Cell Therapy (REACT) | Type 2 Diabetes Mellitus, Chronic Kidney Disease | 10 | 2018-04-25 | 2022-11-17actual | — | 2025-03-24 |
| AZN | AstraZeneca | — | Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient CharacteristicsNCT05953701observationalPercentage of patients with diagnosed CKD | — | Completed | — | Chronic Kidney Diseases | 800,211 | 2023-07-26 | 2023-09-30actual | — | 2025-03-19 |
| PROK | Prokidney | $85M | A Study of Participants With Chronic Kidney Disease Previously Treated With REACTNCT05694169Primary Endpoints is as follows: | Phase 1 | Terminatedsponsor's stated reason: business decision | Biological: Renal Autologous Cell Therapy (REACT) | Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases | 1 | 2023-07-11 | 2024-03-19actual | — | 2025-02-28 |
| PROK | Prokidney | $85M | Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen ProductNCT06790498observationalLong-term safety of REACT follow-up after completing their enrollment in the investigational clinical studies. | — | Enrolling by invitation | Biological: Renal Autologous Cell Therapy (REACT) | Diabetic Kidney Disease, Chronic Kidney Disease | 50 | 2023-11-23 | 2030-05-31 | in 1,380 d | 2025-01-24 |
| AZN | AstraZeneca | — | A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusNCT04515849results2025-01-17The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks | Phase 2 | Completed | Drug: Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms, Semaglutide, Placebo | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 248 | 2020-08-31 | 2022-03-08actual | — | 2025-01-17 |
| AZN | AstraZeneca | — | Dapagliflozin Post Marketing Surveillance in HF and CKDNCT05134701observationalIncidence (%) of adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs, unexpected SAEs, SADRs | — | Completed | — | Heart Failure, Chronic Kidney Disease | 815 | 2022-03-10 | 2024-05-20actual | — | 2025-01-13 |
| AZN | AstraZeneca | — | A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseaseNCT04492722results2023-12-26Change From Baseline in Reduction of Urine Albumin to Creatinine Ratio (ACR) to Week 20 | Phase 2 | Terminatedsponsor's stated reason: The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study. | Drug: AZD5718, Dapagliflozin 10 mg, Placebo | Chronic Kidney Disease | 613 | 2020-10-01 | 2022-09-06actual | — | 2024-12-20 |
| AZN | AstraZeneca | — | REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney DiseaseNCT04847531observationalPrevalence of undiagnosed stage 3 chronic kidney disease (CKD) | — | Completed | — | Chronic Kidney Disease | 1,006,361 | 2020-12-15 | 2023-11-13actual | — | 2024-12-16 |
| AZN | AstraZeneca | — | Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney DiseaseNCT04595370results2024-11-19Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 | Phase 2 | Completed | Drug: AZD9977, Dapagliflozin | Heart Failure, Chronic Kidney Disease | 153 | 2021-01-26 | 2023-09-22actual | — | 2024-11-19 |
| HUMA | Humacyte, Inc. | $162M | Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRDNCT01744418HAVG safety & tolerability | Not applicable | Completed | Device: HAVG graft implantation | End-stage Renal Disease, Kidney Failure, Chronic | 40 | 2012-11-22 | Dec 2014actual | — | 2024-11-13 |
| 4503.T | Astellas Pharma Inc | $26.0B | Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in JapanNCT02510274Safety assessed by adverse events: Part 1 | Phase 1 | Completed | Drug: ASP3325 | Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis | 24 | 2014-05-12 | 2014-11-04actual | — | 2024-11-05 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With AnemiaNCT02964936Change from baseline in hemoglobin (Hb) response rate | Phase 3 | Completed | Drug: roxadustat | Chronic Kidney Disease | 100 | 2017-01-11 | 2018-08-15actual | — | 2024-10-31 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With AnemiaNCT02988973Change from baseline in the average Hemoglobin (Hb) | Phase 3 | Completed | Drug: roxadustat, DA | Chronic Kidney Disease | 334 | 2017-01-12 | 2019-09-13actual | — | 2024-10-31 |
| 4503.T | Astellas Pharma Inc | $26.0B | ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-NCT01964196Rate of rise in Hb (g/dL/week) at Week 6 | Phase 2 | Completed | Drug: ASP1517, Placebo | Anemia in Chronic Kidney Disease Patients Not on Dialysis | 107 | 2013-09-17 | 2015-07-06actual | — | 2024-10-30 |
| 4503.T | Astellas Pharma Inc | $26.0B | Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney DiseaseNCT02805348observationalChange from baseline in the serum concentrations of phosphate | — | Completed | Drug: Bixalomer | Chronic Kidney Disease | 144 | 2016-06-01 | 2018-12-31actual | — | 2024-10-16 |
| LSTA | Lisata Therapeutics, Inc. | $10M | CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)NCT04990427Serious Adverse Events | Phase 1 | Completed | Drug: CLBS201 | Chronic Kidney Diseases | 6 | 2022-01-10 | 2023-01-26actual | — | 2024-10-09 |
| PROK | Prokidney | $85M | A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney DiseaseNCT05286853Primary Composite Endpoint | Phase 3 | Withdrawnsponsor's stated reason: Rilparencel is eligible for initial FDA/ RMAT approval pathway upon successful completion Phase3 REGEN006 (PROACT1) trial. Discontinued Phase3 REGEN016 (PROACT2) focused on enrollment outside the US and is not required for initial US registration. | Biological: Renal Autologous Cell Therapy (REACT) · Procedure: Sham Comparator | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 0 | 2024-07-17 | 2024-09-03actual | — | 2024-09-25 |
| AZN | AstraZeneca | — | Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)NCT04724837results2024-07-30Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12 | Phase 2 | Completed | Drug: Zibotentan, Dapagliflozin, Placebo | Chronic Kidney Disease | 542 | 2021-04-28 | 2023-06-01actual | — | 2024-07-30 |
| NVO | Novo Nordisk A/S | — | A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among NephrologistsNCT06322641observationalNephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation | 300 | 2024-03-26 | 2024-05-10actual | — | 2024-07-26 |
| LMAT | LeMaitre Vascular | $1.9B | Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access GraftsNCT00131872Primary or assisted primary patency at 1 year | Phase 2 | Terminated | Device: Expedial Vascular Access Graft | End Stage Renal Disease | 172 | Mar 2004 | — | — | 2024-07-08 |
| UNCY | Unicycive Therapeutics, Inc | $157M | A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on DialysisNCT06218290Incidence of treatment-related AEs leading to study drug discontinuation during the Maintenance Period. | Phase 2 | Completed | Drug: Oxylanthanum Carbonate | Chronic Kidney Disease Requiring Chronic Dialysis | 106 | 2023-12-15 | 2024-05-29actual | — | 2024-06-24 |
| AZN | AstraZeneca | — | A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)NCT04655027results2024-04-22Difference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours) | Phase 4 | Completed | Drug: Roxadustat, rHuEPO | Anemia of Chronic Kidney Disease | 25 | 2021-02-22 | 2021-10-12actual | — | 2024-04-22 |
| AZN | AstraZeneca | — | OPTIMISE-CKD Drug UtilizationNCT05932901observationalBaseline demographics | — | Completed | — | Chronic Kidney Disease | 2,682,052 | 2022-05-04 | 2023-09-28actual | — | 2024-04-17 |
| HUMA | Humacyte, Inc. | $162M | Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for DialysisNCT04135417results2024-02-23Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAV | Phase 2 | Completed | Biological: HAV | Renal Failure, End Stage Renal Disease, Vascular Access, Hemodialysis | 30 | 2019-11-12 | 2021-05-15actual | — | 2024-03-19 |
| AZN | AstraZeneca | — | A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of LifeNCT04034992observationalConstruct a cohort of patients with CKD | — | Completed | — | Chronic Kidney Disease | 1,052 | 2019-09-11 | 2023-06-30actual | — | 2024-03-06 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney FunctionNCT05094934AUC0-24h,0434,Day10: the area under the NNC0385-0434 plasma concentration-time curve from time 0 to 24 hours after last dose of oral NNC0385-0434 | Phase 1 | Terminatedsponsor's stated reason: Business decision | Drug: NNC0385-0434 A 100 mg | Chronic Kidney Disease | 60 | 2021-11-09 | 2022-07-15actual | — | 2023-12-26 |
| PROK | Prokidney | $85M | A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).NCT04115345Assess change in eGFR and observe incidence of renal-specific procedure and/or product related adverse events (AEs) through 18 months following two Renal Autologous Cell Therapy (REACT) injections [Safety]. | Phase 1 | Completed | Biological: Renal Autologous Cell Therapy (REACT) | Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract | 6 | 2019-08-13 | 2023-01-31actual | — | 2023-12-21 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney DiseaseNCT00849316observationalIncidence of major hypoglycaemic episodes | — | Withdrawnsponsor's stated reason: Due to company decision to focus resources on the finalisation of three ongoing studies in the region | Drug: insulin aspart | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Kidney Disease | 0 | Feb 2009 | Nov 2009 | — | 2023-11-02 |
| BIIB | Biogen | $31.4B | A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 DiabetesNCT01500798Measured GFR assessed by plasma clearance of Tc99m-DTPA | Phase 1 | Terminatedsponsor's stated reason: IDMC recommendation for safety concerns | Drug: 20 mg bardoxolone methyl, Placebo | Chronic Kidney Disease, Type 2 Diabetes | 18 | 2012-01-31 | 2012-11-01actual | — | 2023-10-27 |
| AZN | AstraZeneca | — | Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney DiseaseNCT04727528results2023-10-06Occurrence (Yes/no) of Participants Having Normal Serum Potassium (sK+) Between 3.5 and 5.0 mmol/L Inclusive at End of Treatment (EOT) Without Need for Rescue Treatment for Hyperkalemia at Any Point During the Randomized Phase | Phase 3 | Terminatedsponsor's stated reason: The study was stopped due to a higher than expected screen fail rate (83%) which lead to very low patient enrollment into the study. It should be noted that the decision to terminate the study is not related to safety concerns. | Drug: Sodium zirconium cyclosilicate, Placebo | Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease | 39 | 2021-03-22 | 2022-09-14actual | — | 2023-10-06 |
| OM | Outset Medical | $79M | The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300NCT05947708Adequacy of Chronic Dialysis | Not applicable | Completed | Device: Dialysate Flow Rate | End Stage Renal Disease on Dialysis | 41 | 2019-09-15 | 2019-10-15actual | — | 2023-07-17 |
| PFE | Pfizer | $155.3B | Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease SubjectsNCT00810732results2023-07-06Change From Baseline in Mean 24-Hour Urine Total Protein Level at Week 6 | Phase 2 | Completed | Drug: Open, Nifedipine, Placebo | Chronic Kidney Disease | 27 | 2007-05-09 | 2009-03-06actual | — | 2023-07-06 |
| NVO | Novo Nordisk A/S | — | A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among CardiologistsNCT05755373observationalCardiologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD. Multi-select from a defined list. | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 602 | 2023-03-24 | 2023-05-15actual | — | 2023-06-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Chronic Kidney Disease is matched — 24 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Chronic Kidney Disease
- End Stage Renal Disease
- Chronic Kidney Diseases
- Chronic Kidney Disease (CKD)
- End-Stage Renal Disease
- Anemia of Chronic Kidney Disease
- Dialysis-Dependent Chronic Kidney Disease
- End Stage Renal Disease (ESRD)
- Chronic Kidney Disease and Hypertension
- Chronic Kidney Disease stage3
- Chronic Kidney Disease stage4
- ESRD (End-Stage Renal Disease)
- End Stage Renal Disease on Dialysis
- Anemia Associated With Chronic Kidney Disease
- Anemia in Chronic Kidney Disease Patients Not on Dialysis
- CKD Stage 3
- CKD Stage 4
- Chronic Kidney Disease Requiring Chronic Dialysis
- Chronic Kidney Disease Stage 5
- Chronic Kidney Disease With High Proteinuria
- Chronic Kidney Disease, Secondary Hyperparathyroidism
- Chronic Kidney Failure
- End-stage Renal Disease (ESRD)
- Non-Dialysis-Dependent Chronic Kidney Disease
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Chronic Kidney Disease” (a text search, wider than this page)